Compare STRIDES PHARMA SCIENCE with ALEMBIC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ALEMBIC - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

ALEMBIC 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE ALEMBIC STRIDES PHARMA SCIENCE/
ALEMBIC
 
P/E (TTM) x 43.6 78.6 55.4% View Chart
P/BV x 2.0 6.8 30.0% View Chart
Dividend Yield % 0.2 0.2 158.7%  

Financials

 STRIDES PHARMA SCIENCE   ALEMBIC
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ALEMBIC
Mar-18
STRIDES PHARMA SCIENCE/
ALEMBIC
5-Yr Chart
Click to enlarge
High Rs1,14772 1,593.1%   
Low Rs64234 1,893.8%   
Sales per share (Unadj.) Rs317.24.7 6,749.1%  
Earnings per share (Unadj.) Rs7.86.1 128.5%  
Cash flow per share (Unadj.) Rs25.16.2 401.2%  
Dividends per share (Unadj.) Rs2.000.20 1,000.0%  
Dividend yield (eoy) %0.20.4 59.2%  
Book value per share (Unadj.) Rs274.340.7 674.5%  
Shares outstanding (eoy) m89.50267.03 33.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.811.3 25.0%   
Avg P/E ratio x114.08.7 1,314.4%  
P/CF ratio (eoy) x35.78.5 421.1%  
Price / Book Value ratio x3.31.3 250.5%  
Dividend payout %25.53.3 778.1%   
Avg Mkt Cap Rs m80,05814,139 566.2%   
No. of employees `0002.5NA-   
Total wages/salary Rs m4,341207 2,092.8%   
Avg. sales/employee Rs Th11,325.8NM-  
Avg. wages/employee Rs Th1,731.4NM-  
Avg. net profit/employee Rs Th280.1NM-  
INCOME DATA
Net Sales Rs m28,3941,255 2,262.1%  
Other income Rs m941370 254.1%   
Total revenues Rs m29,3341,625 1,804.7%   
Gross profit Rs m3,965111 3,569.2%  
Depreciation Rs m1,54038 4,075.1%   
Interest Rs m1,9622 115,435.3%   
Profit before tax Rs m1,403442 317.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1681,212 -13.9%   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m9724 406.3%   
Profit after tax Rs m7021,630 43.1%  
Gross profit margin %14.08.9 157.8%  
Effective tax rate %6.95.4 127.9%   
Net profit margin %2.5129.8 1.9%  
BALANCE SHEET DATA
Current assets Rs m24,8361,867 1,330.2%   
Current liabilities Rs m18,993591 3,212.6%   
Net working cap to sales %20.6101.6 20.2%  
Current ratio x1.33.2 41.4%  
Inventory Days Days7194 75.3%  
Debtors Days Days11374 154.2%  
Net fixed assets Rs m34,2891,791 1,914.6%   
Share capital Rs m895534 167.6%   
"Free" reserves Rs m23,65110,324 229.1%   
Net worth Rs m24,54610,858 226.1%   
Long term debt Rs m15,51341 37,653.4%   
Total assets Rs m65,43711,591 564.6%  
Interest coverage x1.7260.9 0.7%   
Debt to equity ratio x0.60 16,655.9%  
Sales to assets ratio x0.40.1 400.7%   
Return on assets %4.114.1 28.9%  
Return on equity %2.915.0 19.1%  
Return on capital %6.915.2 45.4%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m15,69719 80,912.9%   
Fx outflow Rs m735264 278.8%   
Net fx Rs m14,962-244 -6,121.3%   
CASH FLOW
From Operations Rs m1,871236 793.3%  
From Investments Rs m5,826-224 -2,600.8%  
From Financial Activity Rs m-10,157-27 38,183.8%  
Net Cashflow Rs m-2,615-15 17,668.2%  

Share Holding

Indian Promoters % 27.7 64.0 43.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.2 18,900.0%  
FIIs % 8.6 9.7 88.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 26.1 99.2%  
Shareholders   56,241 54,701 102.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   NEULAND LABS  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 11, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS